A Study of Galcanezumab (LY2951742) in Healthy Chinese Participants

NCT04085289 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Galcanezumab
DRUG: Placebo

Sponsor

Eli Lilly and Company